BMS-605541 is an Orally Active VEGFR-2 Kinase Inhibitor for Cancer Research
Tumor-induced angiogenesis, or the formation of new capillary networks between neoplastic cells and endothelial cells of the host, is required for solid tumor growth and metastases. In addition, the Vascular endothelial growth factor receptor (VEGFR) is an important receptor tyrosine kinase (RTK) in the induction of angiogenesis. As a...